Results 171 to 180 of about 6,610 (202)
FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer
Applied Immunohistochemistry & Molecular Morphology, 2022 Clinical trials in patients with ER+ breast cancer with or without FGFR pathway somatic alterations have shown limited clinical benefit from treatment with FGFR tyrosine kinase inhibitors alone or in combination with endocrine therapy. This is likely because of an inadequate predictive biomarker to select appropriate patients.
Gonzalez-Ericsson, Paula I +6 more
openaire +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Oral Oncology, 2007
Chromosomal aberrations are known to have an impact on the initiation and progression of oral squamous cell carcinoma (OSCC), but individual genes involved in OSCC pathogenesis are poorly described. To elucidate the molecular events underlying oral carcinogenesis, a set of primary OSCC were screened for distinct genetic imbalances by means of array ...
Bernhard Radlwimmer +2 more
exaly +3 more sources
Chromosomal aberrations are known to have an impact on the initiation and progression of oral squamous cell carcinoma (OSCC), but individual genes involved in OSCC pathogenesis are poorly described. To elucidate the molecular events underlying oral carcinogenesis, a set of primary OSCC were screened for distinct genetic imbalances by means of array ...
Bernhard Radlwimmer +2 more
exaly +3 more sources
European Journal of Cancer, 2021 Amplification of fibroblast growth factor receptor 1 (FGFR1) in non-small cell lung cancer (NSCLC) has been considered as an actionable drug target. However, pan-FGFR tyrosine kinase inhibitors did not demonstrate convincing clinical efficacy in FGFR1 ...
Linnea la Fleur +2 more
exaly +2 more sources
Journal of Thoracic Oncology, 2019 Introduction There is substantial evidence for the oncogenic effects of fibroblast growth factor receptor 1 (FGFR1) in many types of cancer, including lung cancer, but the role of this receptor has not been addressed specifically in lung adenocarcinoma ...
Luis Paz-Ares +2 more
exaly +2 more sources
Neuronal FGFR1 transactivation by inducing FGFR1/5-HT1A heteroreceptor complexes formation
, 2011 There are no clear data on the molecular mechanism by which the hippocampal 5-HT transmission contributes to the neuroprotective and antidepressant effects of 5-HT uptake blockers. Previously, we revealed that a 5-HT1A agonist may induce phosphorylation of FGFR1 and ERK1/2 in rat hippocampus independent of FGF-2, suggesting transactivation of FGFR1 ...
FRINCHI, Monica +7 more
openaire +2 more sources
Abstract A20: FGFR1-amplified squamous cell lung cancers depend on FGFR1
Clinical Cancer Research, 2010Abstract In lung adenocarcinomas of never-smokers EGFR mutations or EML4-ALK gene fusions are frequent genomic events that both expose prime therapeutic targets. By contrast, squamous cell lung cancer (SQLC) is almost invariably associated with smoking; in this subgroup of patients, no attractive therapeutic target has so far been ...
Martin L. Sos, Roman K. Thomas
openaire +1 more source
FGFR1 and FGFR2 Mutations in Pfeiffer Syndrome
Journal of Craniofacial Surgery, 2013Pfeiffer syndrome (PS) (MIM 101600) is one of the most common syndromic forms of craniosynostosis. It is characterized by craniosysnostosis, midface hypoplasia, broad and medially deviated thumbs, and great toes with partial syndactyly of the digits. Here, we described clinical and genetic features of 12 unrelated Thai individuals with PS.
Chayanin, Chokdeemboon +5 more
openaire +2 more sources
Virchows Archiv, 2016
Although lung cancer continues to be the leading cause of cancer-related death, accurate diagnosis followed by personalized treatment is expected to raise the 5-year survival rate. Targeted therapies are now in routine clinical use, in particular for lung adenocarcinoma (ADC).
Vitor, Sousa +8 more
openaire +2 more sources
Although lung cancer continues to be the leading cause of cancer-related death, accurate diagnosis followed by personalized treatment is expected to raise the 5-year survival rate. Targeted therapies are now in routine clinical use, in particular for lung adenocarcinoma (ADC).
Vitor, Sousa +8 more
openaire +2 more sources
Journal of Hematopathology
Background Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of FGFR1(MLN-FGFR1), also referred to as 8p11 myeloproliferative syndrome (EMS), arises from aberrant FGFR1 gene rearrangement in bone marrow hematopoietic stem cells, resulting in the transformation of myeloid/lymphoid cells into neoplastic growths.
Xianqi, Feng +9 more
openaire +2 more sources
Background Myeloid/lymphoid neoplasm with eosinophilia and rearrangement of FGFR1(MLN-FGFR1), also referred to as 8p11 myeloproliferative syndrome (EMS), arises from aberrant FGFR1 gene rearrangement in bone marrow hematopoietic stem cells, resulting in the transformation of myeloid/lymphoid cells into neoplastic growths.
Xianqi, Feng +9 more
openaire +2 more sources
2010
Proteinkinase FGFR1 plays a key role in angiogenesis regulation and tumor proliferation. Inhibitors of this kinase can be used for effective treatment of solid tumors and proliferative diseases. FGFR1 inhibitors searching were performed among 3500 chromone derivatives by virtual screening and in vitro testing.
openaire +1 more source
Proteinkinase FGFR1 plays a key role in angiogenesis regulation and tumor proliferation. Inhibitors of this kinase can be used for effective treatment of solid tumors and proliferative diseases. FGFR1 inhibitors searching were performed among 3500 chromone derivatives by virtual screening and in vitro testing.
openaire +1 more source